Ovarian Cancer Drugs Market Revenue to Attain USD 7.78 Bn by 2035

Published: 01 Apr 2026

Author: Precedence Research

Share:

Ovarian Cancer Drugs Market Revenue and Trends 2026 to 2035

The global ovarian cancer drugs market revenue surpassed USD 4.09 billion in 2025 and is predicted to attain around USD 7.78 billion by 2035, growing at a CAGR of 6.64%. The market is driven by the rising demand for effective and targeted therapies for treatment-resistant ovarian cancer.

Driving Innovation: The Evolving Ovarian Cancer Drugs Market

The ovarian cancer drugs market refers to the global industry focused on the development, production, and commercialization of therapeutics used to treat ovarian cancer. Advancements in the field of molecular biology have led to the development of specific drugs like PARP inhibitors and anti-angiogenic medications, which are enhancing the treatment of patients and stimulating market growth. The market is growing rapidly due to the rising demand for personalized medicine and increasing investments by pharmaceutical companies in research & development.

Segment Insights

• By therapeutic class, the PARP Inhibitors segment held the largest market share in 2025, owing to their proven clinical efficacy in treating patients with BRCA-mutated and homologous recombination deficiency (HRD)-positive ovarian cancer. Their use has increased as maintenance therapy after the use of platinum-based chemotherapy.
• By treatment type, the targeted therapy segment contributed the highest market share of 44.3% in 2025 because of its ability to target the cancer cells and produce minimal damage to normal tissues, making it the preferred choice. This therapy has fewer side effects than traditional chemotherapy, which enhances patient compliance.
• By tumor type, the epithelial ovarian cancer segment held a major market share in 2025 because it is the most prevalent type of ovarian cancer. This type of cancer has a high incidence rate, which has led to an increased number of patients being treated. The majority of approved medicines and studies in clinical research are mostly on epithelial ovarian cancer, which is making treatment more available.
• By distribution channel, the hospital pharmacies segment held the largest market share of 57.1% in 2025 due to the fact that the majority of ovarian cancer therapies are used in hospitals. Complicated treatments like chemotherapy and specific biologics can be easily done by professionals in hospitals.

Regional Insights

North America led the global ovarian cancer drugs market in 2025 because of its well-developed healthcare system and well-established pharmaceutical and biotechnology sectors. High healthcare spending has enabled access to costly therapies, including targeted and biologic treatments. Additionally, efficient regulatory frameworks and faster drug approvals, particularly by the U.S. Food and Drug Administration, have accelerated the introduction of novel therapies in the region.

Asia Pacific is expected to be the fastest-growing region in the market during the forecast period, driven by improving healthcare infrastructure and rising healthcare spending in emerging economies such as India and China. The region’s large and growing patient population, along with increasing awareness about ovarian cancer and its treatments, supports market expansion. Government investments in cancer care facilities, screening programs, and drug availability, combined with the presence of global pharmaceutical companies and local manufacturers offering more affordable treatments, further boost growth.

Ovarian Cancer Drugs Market Coverage

Recent Development

• In March 2026, Lifyorli (relacorilant) in combination with nab-paclitaxel to treat platinum-resistant cancerous ovarian cancers was approved by the U.S. Food and Drug Administration for use by Corcept Therapeutics Incorporated. It is the first accepted selective glucocorticoid receptor antagonist (SGRA) for ovarian cancer.(Source: https://ir.corcept.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8261

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344